Evidence map›Paper›PMID 33399923›Full record

ArticleDer Nervenarzt2021

[Current aspects of neurogenic dysfunctions of the lower urinary tract in multiple sclerosis].

Burkhard Domurath, Peter Flachenecker, Thomas Henze, Wolfgang Feneberg, Anna Brandt, Ines Kurze, Ruth Kirschner-Hermanns, Albert Kaufmann, Jörn Bremer, Manuela Vonthien and 4 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Der Nervenarzt, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Burkhard DomurathNeuro-Urologisches Zentrum, Kliniken Beelitz GmbH, Paracelsusring 6A, 14547, Beelitz Heilstätten, Deutschland. bdomurath@yahoo.de.
Peter FlacheneckerNeurologisches Rehabilitationszentrum Quellenhof, Bad Wildbad, Deutschland.
Thomas HenzePraxis für Neurologie Dr. Blersch, Regensburg, Deutschland.
Wolfgang FenebergMarianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gemeinnützige GmbH, Berg, Deutschland.
Anna BrandtNeurologisches Zentrum, Segeberger Kliniken, Bad Segeberg, Deutschland.
Ines KurzeQuerschnittgelähmten-Zentrum, Klinik für Paraplegiologie und Neuro-Urologie, Zentralklinik Bad Berka GmbH, Bad Berka, Deutschland.
Ruth Kirschner-HermannsSektion Neurourologie, Klinik für Urologie und Kinderurologie, Universitätsklinikum Bonn und Neuro-Urologie, Neurologisches Rehabilitationszentrum der "Godeshöhe" e. V., Bonn, Deutschland.
Albert KaufmannZentrum für Kontinenz und Neuro-Urologie, Kliniken Maria Hilf GmbH, Mönchengladbach, Deutschland.
Jörn BremerQuerschnittgelähmtenzentrum, BDH Klinik Greifswald gGmbH, Greifswald, Deutschland.
Manuela VonthienColoplast GmbH, Kühnstr. 75, 22045, Hamburg, Deutschland.
Kerstin RateringColoplast GmbH, Kühnstr. 75, 22045, Hamburg, Deutschland.
Christoph SchäferRehaklinik für Neurologie und Orthopädie, Johanniter-Klinik am Romberg, Dortmund, Deutschland.
Will Nelson VanceNeuro-Urologisches Zentrum, Kliniken Beelitz GmbH, Paracelsusring 6A, 14547, Beelitz Heilstätten, Deutschland.
Paul SchmidtStatistik, Große Seestraße, 813086, Berlin, Deutschland.
Coloplast (Germany) · DENeurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson · DEInstitut für Angewandte Statistik · DEKliniken Maria Hilf · DENeurologisches Rehabilitationszentrum Quellenhof Bad Wildbad · DEOrthopädische Praxis · DESegeberger Kliniken · DEUniversitätsmedizin Greifswald · DEUniversity Hospital Bonn · DEZentralklinik Bad Berka · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the clinical management of patients with multiple sclerosis (MS), the challenge is to make an early diagnosis and initiate adequate treatment of neurogenic disorders of the lower urinary tract (NLUTD). Various national guidelines provide practical recommendations which are sometimes discordant.

objectiveTo develop a simple evidence-based algorithm for detecting NLUTD in patients with MS that could be taken as a principle for deriving therapeutic consequences. MATERIAL AND

methodsA prospective multicenter study was initiated as a direct result of two multidisciplinary conferences. The aim was to identify statistically and clinically relevant parameters for the routine diagnosis of NLUTD in patients with MS. Urodynamic abnormalities served as the gold standard. At three subsequent consensus conferences, the results of the study were discussed, a diagnostic algorithm was developed and consensus was reached on a first-line treatment. RESULTS AND DISCUSSION: The proposed algorithm enables the detection of NLUTD in patients with MS with the help of four statistically significant predictors: 1) the residual urine volume, 2) the number of urinary tract infections (UTI) within the last 6 months, 3) the standardized micturition frequency and 4) the presence/absence of urinary incontinence. The newly developed algorithm has proved to be efficient with the following results: approximately 75% of the patients do not need a urodynamic examination for a first-line treatment decision. In 25% of cases, urodynamic examinations are essential for an adequate treatment decision. Routine assessments include the patient medical history, residual urine volume measurement, a micturition diary and a uroflowmetry (optional).

Indexed as

Multiple SclerosisUrologic DiseasesHumansProspective StudiesUrodynamicsAssessmentsBladder dysfunctionMultiple sclerosisNeurogenic lower urinary tract disorders (NLUTD)Urodynamics

Identifiers

PMID33399923
PMCPMC8026406
OpenAlexW3120567600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.